WRAP TECHNOLOGIES, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors that purchased Wrap Technologies, Inc.

RAPIDLY APPROACHING LEAD PLAINTIFF DEADLINE IS NOVEMBER 23, 2020

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action  lawsuit  has  been  filed in the United States District Court for the

Central District of California on behalf of investors that purchased Wrap Technologies, Inc. (NASDAQ: WRTC) (the “Company”)  securities between July 31, 2020 and September 23, 2020, inclusive (the “Class Period”).

All
 investors who purchased shares of
Wrap Technologies, Inc.
,
and incurred losses are urged
to contact the firm immediately at  [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

If you  have  incurred  losses  in  the  shares of against Wrap Technologies, Inc.,you may,no later than November 23, 2020,  request that the Court appoint you lead plaintiff of the proposed class.  Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Wrap Technologies, Inc.  


CLICK HERE TO JOIN CASE

On September 23, 2020, White Diamond Research published a report entitled “Wrap Technologies: Disastrous LAPD BolaWrap Pilot Program Results, No Evidence These Have Been Communicated To Investors” alleging, among other things, that the Company’s trial pilot program with the LAPD was a disaster, and that the Company had not disclosed the results to investors.

On this news, securities of Wrap fell $2.07  per  share, or 25.43%,  to close at $6.07 per share.


Wolf Haldenstein
has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at  www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected] 
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. 

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors that purchased Wrap Technologies, Inc. (NASDAQ: WRTC) securities between July 31, 2020 and September 23, 2020 (the “Class Period”). Investors have until November 23, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

On September 23, 2020, White Diamond Research published a report entitled “Wrap Technologies: Disastrous LAPD BolaWrap Pilot Program Results, No Evidence These Have Been Communicated To Investors” alleging, among other things, that the Company’s trial pilot program with the LAPD was a disaster, and that the Company had not disclosed the results to investors.

On this news, securities of Wrap fell $2.07 per share, or 25.43% to close at$6.07 per share on September 23, 2020.

The complaint, filed on September 23, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had concealed the results of the LAPD BolaWrap pilot program, which demonstrated that the BolaWrap was ineffective, expensive, and sparingly used in the field; and (2) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/wrap-technologies-inc-class-action-alert-wolf-haldenstein-adler-freeman–herz-llp-reminds-investors-that-a–securities–class–action–lawsuit–has–been–filed–in–the–united-states-district-court-for-the-central-district-o-301172416.html

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

National Storage Affiliates Trust Announces Increase in Quarterly Common Dividend

National Storage Affiliates Trust Announces Increase in Quarterly Common Dividend

GREENWOOD VILLAGE, Colo.–(BUSINESS WIRE)–
National Storage Affiliates Trust (“NSA” or the “Company”) (NYSE: NSA), today announced its Board of Trustees declared regular cash dividends for the fourth quarter 2020 payable on December 31, 2020 to shareholders of record on December 15, 2020 on the following securities:

  • a dividend of $0.35 per common share, representing an annualized dividend rate of $1.40. The new rate represents a 6.1% increase from the fourth quarter 2019 dividend rate; and
  • a dividend of $0.375 per share on the Company’s 6.000% Series A Cumulative Redeemable Preferred Shares.

Tamara Fischer, President and Chief Executive Officer, commented, “We are pleased to be able to raise the dividend for the second time this year, as our operations continue to benefit from our differentiated PRO structure as well as the resilience of the self storage sector.”

Upcoming Industry Conference

NSA management is scheduled to participate in the Nareit REITworld 2020 Virtual Conference, November 17-19, 2020.

About National Storage Affiliates Trust

National Storage Affiliates Trust is a real estate investment trust headquartered in Denver, Colorado, focused on the ownership, operation and acquisition of self storage properties located within the top 100 metropolitan statistical areas throughout the United States. As of September 30, 2020, the Company held ownership interests in and operated 788 self storage properties located in 35 states and Puerto Rico with approximately 49.5 million rentable square feet. NSA is one of the largest owners and operators of self storage properties among public and private companies in the United States. For more information, please visit the Company’s website at www.nationalstorageaffiliates.com. NSA is included in the MSCI US REIT Index (RMS/RMZ), the Russell 2000 Index of Companies and the S&P SmallCap 600 Index.

National Storage Affiliates Trust

Investor/Media Relations

George Hoglund, CFA

Vice President – Investor Relations

720.630.2160

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Construction & Property REIT

MEDIA:

GOHEALTH, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that it has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against GoHealth, Inc.

APPROACHING LEAD PLAINTIFF DEADLINE ON NOVEMBER 20, 2020

PR Newswire

 
NEW YORK and CHICAGO, Nov. 12, 2020 /PRNewswire/ — Wolf Haldenstein Adler Freeman & Herz LLP  reminds investors that  it has filed a  federal  securities  class  action  lawsuit  against GoHealth, Inc.  (“GoHealth” or the “Company”) (NASDAQ: GOCO).   The class action, filed in United States District Court for the Northern District of Illinois, Eastern Division, and docketed under 1:20-cv-05765, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth’s July 2020 initial public offering (the “IPO”). Wolf Haldenstein is seeking to pursue remedies under the Securities Act of 1933 (the “Securities Act”) against GoHealth, certain of GoHealth’s officers and directors, and the private equity sponsor of the IPO and its affiliates.

All
 investors who purchased shares of
GoHealth
and incurred losses are urged
to contact the firm immediately at  [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

If you  have  incurred  losses  in  the  shares of against  GoHealth.,you may,no later than November 20, 2020,  request that the Court appoint you lead plaintiff of the proposed class.  Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of GoHealth.


CLICK HERE TO JOIN CASE

On June 19, 2020, GoHealth filed a registration statement  with the United States Securities and Exchange Commission (“SEC”) for the IPO on Form S-1 (the “Registration Statement”), which was used to sell to the investing public 43.5 million shares of GoHealth Class A common stock at $21 per share, for total gross proceeds of $913.5 million.

Our complaint alleges that the Offering Materials for the IPO were negligently prepared and, as a result, contained untrue statements of material fact, omitted material facts necessary to make the statements contained therein not misleading, and failed to make necessary disclosures required under the rules and regulations governing their preparation. Specifically, the Offering Materials failed to disclose that at the time of the IPO:

  • the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020;
  • GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base;
  • GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company’s concentrated carrier business model, and GoHealth’s efforts to expand into new geographies, develop new carrier partnerships and worsening product mix;
  • GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and
  • these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the IPO.

Since the July 2020 IPO, the price of GoHealth Class A common stock has suffered significant price declines. By September 15, 2020, GoHealth Class A common stock closed at just $12.53 per share – over 40% below the $21 per share price investors paid for the stock in the IPO nearly two months prior.


Wolf Haldenstein
has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at  www.whafh.com.

Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected] 
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/gohealth-inc-class-action-alert-wolf-haldenstein-adler-freeman–herz-llp-reminds-investors-that-it–has–filed–a–securities–class–action–lawsuit–in–the–united-states-district-court-for-the-northern-district-of-illinois-301172411.html

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

GCC Obtained a Favorable Resolution in the Annulment of the Damages Award, All Legal Proceedings in Bolivia Have Been Exhausted

CHIHUAHUA, Mexico, Nov. 12, 2020 (GLOBE NEWSWIRE) — Grupo Cementos de Chihuahua, S.A.B. de C.V. (BMV: GCC*, or “the Company”), a leading producer of cement and concrete in the United States and Mexico, announced today that it has obtained a favorable resolution in the annulment of the “Damages Award”, in the arbitration process commenced by Compañía de Inversiones Mercantiles, S.A. (“CIMSA”), against the Company and pursuant to the Inter-American Commission on International Commercial Arbitration.

This annulment was notified by the highest constitutional justice authority in Bolivia on October 29th of this year. Consequently, all legal proceedings filed in the country of Bolivia have been resolved in favor of GCC.

Based on this resolution, the Company will commence the corresponding legal proceedings in the United States to reverse the ruling from the District Court of Colorado.

About GCC

GCC is a leading supplier and producer of cement, concrete, aggregates, and construction‐related services in the United States, Mexico and Canada, with an annual cement production capacity of 5.8 million metric tons. Founded in 1941, the Company’s shares are listed on the Mexican Stock Exchange under the ticker symbol GCC*.

Forward-Looking Statements

This press release may contain forward-looking statements. All statements that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “intend,” “project” and similar expressions are generally intended to identify forward-looking statements. These statements are subject to risks and uncertainties including, among others, changes in macroeconomic, political, legal, public health crises including COVID-19, governmental or business conditions in the markets where GCC operates; changes in interest rates, inflation rates and currency exchange rates; performance of the construction industry; and pricing, business strategy and other factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from the beliefs, projections, and estimates described herein. GCC assumes no obligation to update the information contained in this press release.

For
further
information
,
contact
:

GCC Investor Relations

Ricardo Martinez
+52 (614) 442 3176
+ 1 (303) 739 5943
[email protected]

Intact Financial Corporation Announces $1.25 Billion Bought Deal Private Placement of Subscription Receipts to Finance a Portion of the Purchase Price of the Possible Offer for RSA Insurance Group PLC (“RSA”)

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Further to the announcement on November 5, 2020 relating to the possible offer for RSA by Intact Financial Corporation (TSX: IFC) (“Intact” or the “Company”) and Tryg A/S (together with Intact, the “Consortium”) (the “Transaction”), Intact announced today that it has entered into an agreement with a group of underwriters, led by CIBC Capital Markets and Barclays Capital Canada Inc., pursuant to which the underwriters have agreed to purchase, on a bought deal basis, 9,272,000 subscription receipts of the Company (the “Subscription Receipts”) at a price of $134.50 per Subscription Receipt for gross proceeds of $1.25 billion (the “Offering”). The underwriters intend to arrange for substituted purchasers for the Subscription Receipts. The Subscription Receipts will be offered by way of private placement to accredited investors and other exempt purchasers in all provinces and territories of Canada, The Subscription Receipts will be subject to a four month hold period under applicable securities laws in Canada.

Earlier today, Intact announced that it had entered into subscription agreements with institutional investors for the aggregate issuance of 23.8 million subscription receipts at a price of $134.50 per subscription receipt for gross proceeds of $3.2 billion (the “Cornerstone Equity Financing”). The Offering and Cornerstone Equity Financing together provide Intact with all of the equity financing it would require to fund its share of the purchase price for RSA.

The Transaction would generate significant value through loss ratio and expense ratio improvements across the operations of Intact. The acquisition of RSA’s Canadian operations is expected to drive approximately 75% of the value creation, with UK & International operations accounting for approximately 20% and specialty lines accounting for approximately 5%. Over $250 million of pre-tax annual run rate synergies are expected within 36 months, before any risk selection improvements. Intact intends to apply its expertise in digital, data and AI platforms, pricing and risk selection, claims management, and investment and capital management to RSA’s platform to drive profitability.

Should a firm offer be made for RSA, which is subject to, amongst other things, due diligence and reaching definitive agreements with various stakeholders, Intact estimates the proposed Transaction to complete during the second quarter of 2021.

No firm offer has been made, nor can there be any certainty that an offer will be made, for RSA under the UK Takeover Code.

Each Subscription Receipt will entitle the holder to receive one common share of Intact upon closing of the Transaction. Completion of the Offering is conditional upon the Consortium announcing a firm offer for RSA on or prior to closing. Additional information on the proposed transaction is available at Intact’s website at https://www.intactfc.com/English/investors/. The completion of the Offering is also subject to approval of the Toronto Stock Exchange and other customary closing conditions. The offering is expected to close on December 3, 2020

The Subscription Receipts and the common shares of Intact have not been, and will not be, registered under the U.S. Securities Act, or the securities laws of any state of the United States and may not be offered, sold or delivered, directly or indirectly, within the United States, except in certain transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these subscription receipts within the United States.

About
Intact

Intact Financial Corporation is the largest provider of property and casualty (P&C) insurance in Canada and a leading provider of specialty insurance in North America, with over $11 billion in total annual premiums. The Company has approximately 16,000 employees who serve more than five million personal, business and public sector clients through offices in Canada and the U.S.

In Canada, Intact distributes insurance under the Intact Insurance brand through a wide network of brokers, including its wholly-owned subsidiary BrokerLink, and directly to consumers through belairdirect. Frank Cowan Company, a leading MGA, distributes public entity insurance programs including risk and claims management services in Canada.

In the U.S., Intact Insurance Specialty Solutions provides a range of specialty insurance products and services through independent agencies, regional and national brokers, wholesalers and managing general agencies. Products are underwritten by the insurance company subsidiaries of Intact Insurance Group USA, LLC.

For further information please contact:

Intact
Media Inquiries

Jennifer Beaudry
Senior Consultant, External Communications
1 514 282-1914 ext. 87375
[email protected]

Intact
Investor Inquiries

Ryan Penton
Director, Investor Relations
1 416 341-1464 ext. 45112
[email protected]

Forward-looking statements

Certain of the statements included in this press release about the Offering and the Cornerstone Equity Financing, the proposed acquisition of RSA (the “Acquisition”) or any other future events or developments constitute forward-looking statements. The words “may”, “will”, “would”, “should”, “could”, “expects”, “plans”, “intends”, “trends”, “indications”, “anticipates”, “believes”, “estimates”, “predicts”, “likely”, “potential” or the negative or other variations of these words or other similar or comparable words or phrases, are intended to identify forward-looking statements. Unless otherwise indicated, all forward-looking statements in this press release are made as of November 12, 2020, and are subject to change after that date.

Forward-looking statements are based on estimates and assumptions made by management based on management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management believes are appropriate in the circumstances. In addition to other estimates and assumptions which may be identified herein, estimates and assumptions have been made regarding, among other things, the receipt of all requisite approvals in a timely manner and on terms acceptable to the Company, the realization of the expected strategic, financial and other benefits of the Acquisition, and economic and political environments and industry conditions. However, the completion of the Acquisition is expected to be subject to customary closing conditions, termination rights and other risks and uncertainties, including, without limitation, regulatory approvals, and there can be no assurance that the Acquisition will be completed. There can also be no assurance that if the Acquisition is completed, the strategic and financial benefits expected to result from the Acquisition will be realized. Many factors could cause the Company’s actual results, financial performance or condition, or achievements to differ materially from those expressed or implied by the forward-looking statements herein, including, without limitation, the following factors:

  • expected regulatory processes and outcomes in connection with the Company’s business;
  • the Company’s ability to implement its strategy or operate its business as management currently expects;
  • the Company’s ability to accurately assess the risks associated with the insurance policies it writes;
  • unfavourable capital market developments or other factors, including the impact of the COVID-19 pandemic and related economic conditions, which may affect the Company’s investments, floating rate securities and funding obligations under its pension plans;
  • the cyclical nature of the P&C insurance industry;
  • management’s ability to accurately predict future claims frequency and severity, including in the high net worth and personal auto lines of business;
  • government regulations designed to protect policyholders and creditors rather than investors;
  • litigation and regulatory actions, including with respect to the COVID-19 pandemic;
  • periodic negative publicity regarding the insurance industry;
  • intense competition;
  • the Company’s reliance on brokers and third parties to sell its products to clients and provide services to the Company and the impact of COVID-19 and related economic conditions on such brokers and third parties;
  • the Company’s ability to successfully pursue its acquisition strategy;
  • the Company’s ability to execute its business strategy;
  • the uncertainty of obtaining in a timely manner, or at all, the regulatory approvals required to complete the Acquisition, the issuance of the subscription receipts and the issuance of the common shares issuable pursuant to the subscription agreements;
  • unfavourable capital markets developments or other factors that may adversely affect the Company’s ability to finance the Acquisition;
  • the Company’s ability to improve its combined ratio, retain business and achieve synergies and maintain market position arising from successful integration plans relating to the Acquisition, as well as management’s estimates and expectations in relation to future economic and business conditions and other factors in relation to the Acquisition and resulting impact on growth and accretion in various financial metrics;
  • its ability to otherwise complete the integration of the business acquired within anticipated time periods and at expected cost levels;
  • the Company’s dependence on key employees and its ability to attract and retain key employees in connection with the Acquisition;
  • the Company’s ability to achieve synergies arising from successful integration plans relating to acquisitions generally;
  • the Company’s profitability and ability to improve its combined ratio in the United States;
  • the Company’s ability to retain and attract new business in connection with the Acquisition;
  • the Company’s participation in the Facility Association (a mandatory pooling arrangement among all industry participants) and similar mandated risk-sharing pools;
  • terrorist attacks and ensuing events;
  • the occurrence and frequency of catastrophe events, including a major earthquake;
  • catastrophe losses caused by severe weather and other weather-related losses, as well as the impact of climate change;
  • the occurrence of and response to public health crises including epidemics, pandemics or outbreaks of new infectious diseases, including most recently, the coronavirus (COVID-19) pandemic and ensuing events;
  • the Company’s ability to maintain its financial strength and issuer credit ratings;
  • the Company’s access to debt and equity financing;
  • the Company’s ability to compete for large commercial business;
  • the Company’s ability to alleviate risk through reinsurance;
  • the Company’s ability to successfully manage credit risk (including credit risk related to the financial health of reinsurers);
  • the Company’s ability to contain fraud and/or abuse;
  • the Company’s reliance on information technology and telecommunications systems and potential failure of or disruption to those systems, including in the context of the impact on the ability of our workforce to perform necessary business functions remotely, as well as in the context of evolving cybersecurity risk;
  • the impact of developments in technology and use of data on the Company’s products and distribution;
  • changes in laws or regulations, including those adopted in response to COVID-19 that would, for example, require insurers to cover business interruption claims irrespective of terms after policies have been issued, and could result in an unexpected increase in the number of claims and have a material adverse impact on the Company’s results;
  • COVID-19 related coverage issues and claims, including certain class actions and related defence costs could negatively impact our claims reserves;
  • general economic, financial and political conditions;
  • the Company’s dependence on the results of operations of its subsidiaries and the ability of the Company’s subsidiaries to pay dividends;
  • the volatility of the stock market and other factors affecting the trading prices of the Company’s securities, including in the context of the COVID-19 crisis;
  • the Company’s ability to hedge exposures to fluctuations in foreign exchange rates;
  • future sales of a substantial number of the Company’s common shares; and
  • changes in applicable tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof.

All of the forward-looking statements included in this press release are qualified by these cautionary statements and those made in the section entitled Risk Management (Sections 22-27) of our MD&A for the year ended December 31, 2019, the section entitled Risk Management (sections 17-18) of our MD&A for the quarter ended September 30, 2020 and elsewhere in this press release. These factors are not intended to represent a complete list of the factors that could affect the Company. These factors should, however, be considered carefully. Although the forward-looking statements are based upon what management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. Investors should not rely on forward-looking statements to make decisions, and investors should ensure the preceding information is carefully considered when reviewing forward-looking statements contained herein. The Company and management have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Disclaimer

This press release does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever.

The information contained in this press release concerning the Company does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in the Company. The information is qualified entirely by reference to the Company’s publicly disclosed information and the cautionary note regarding forward-looking statements included in this press release.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its the directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this press release and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this press release, the Company does not undertake or agree to any obligation to provide investors with access to any additional information or to update this press release or to correct any inaccuracies in, or omissions from, this press release that may become apparent. The information and opinions contained in this press release are provided as at the date of this press release. The contents of this press release are not to be construed as legal, financial or tax advice. Each investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.

 

Kandi Technologies Announces the Closing of a Registered Direct Placement of $60 Million of Common Stock and Warrants

JINHUA, China, Nov. 12, 2020 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the “Company” or “Kandi”) (NASDAQ GS: KNDI), today announced that it closed a registered direct offering of 9,404,392 units (the “Units”) of its securities at a purchase price per Unit of $6.38, generating aggregate gross proceeds to the Company of approximately $60,000,000, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.  Each Unit consisted of one share of our common stock, and 0.4 warrants to purchase a share of our common stock.  The warrants have an exercise price of $8.18 per share and a term of 30 months, but are not exercisable for the first six months following issuance.  The Company issued a total of 9,404,392 shares of common stock and warrants for the purchase of up to 3,761,757 shares of common stock to the investors in the placement. 

The net proceeds from this offering will be used for general working capital purposes.  

FT Global Capital, Inc. acted as the exclusive placement agent for the transaction.

Pryor Cashman LLP acted as counsel to the Company and Schiff Hardin LLP acted as counsel to the Placement Agent in connection with the placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be sold in any state in which this offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Kandi Technologies Group, Inc.  

Kandi Technologies Group, Inc. (KNDI), headquartered in Jinhua Economic Development Zone, Zhejiang Province, is engaged in the research, development, manufacturing, and sales of various vehicular products. Kandi conducts its primary business operations through its wholly-owned subsidiary, Zhejiang Kandi Vehicles Co., Ltd. (“Kandi Vehicles”) and its subsidiaries including Zhejiang Kandi Smart Battery Swap Technology Co., Ltd, SC Autosports, LLC (d/b/a Kandi America), the wholly-owned subsidiary of Kandi in the United States and Fengsheng Automobile Technology Group Co., Ltd (formerly known as Kandi Electric Vehicles Group Co., Ltd., the “Affiliate Company”). Kandi Vehicles has established itself as one of China’s leading manufacturers of pure electric vehicle parts and off-road vehicles.

In 2013, Kandi Vehicles and Geely Group, China’s leading automaker, jointly invested in the establishment of the Affiliate Company in order to develop, manufacture and sell pure electric vehicle (“EV”) products. Geely Group (including its affiliate) and Kandi Vehicles currently hold 78% and 22% of the equity interests in the Affiliate Company, respectively. The Affiliate Company has established itself as one of the driving forces in the development and the manufacturing of pure EV products in China.

More information about KNDI is available on the Company’s corporate website at http://www.kandivehicle.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,””expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the applicable securities laws, the Company does not assume a duty to update these forward-looking statements.

Follow us on Twitter: @ Kandi_Group

For More Information:

Kandi Technologies Group, Inc.

Ms. Kewa Luo

Phone: +1 (212) 551-3610

Email: [email protected]

The Blueshirt Group

U.S.:

Mr. Gary Dvorchak

Email: [email protected]

China:

Ms. Susie Wang

Email: [email protected]

Teledyne Brown Engineering Awarded $85 Million NASA Contract to Provide Key Stage of NASA’s Space Launch System Vehicle Returning Astronauts to the Moon

Teledyne Brown Engineering Awarded $85 Million NASA Contract to Provide Key Stage of NASA’s Space Launch System Vehicle Returning Astronauts to the Moon

HUNTSVILLE, Ala.–(BUSINESS WIRE)–
Teledyne Brown Engineering, Inc. (TBE), a division of Teledyne Technologies Incorporated (NYSE:TDY), today announced it has been awarded a $85 million contract modification to supply NASA two additional Launch Vehicle Stage Adapters (LVSA) for the Artemis II and III moon missions. The LVSA’s are the largest pieces of the current configuration of the Space Launch System (SLS) to be built at Marshall Space Flight Center (MSFC) in Huntsville, Alabama.

The LVSA provides the physical interface between the SLS Core Stage and the Interim Cryogenic Propulsion Stage (ICPS). It also serves as the critical separation system used to separate the Core Stage of the rocket from ICPS. The cone-shaped adapter is roughly thirty feet in diameter by thirty feet tall and consists of sixteen Aluminum-Lithium 2195 alloy panels.

“TBE is thrilled to be a part of the monumental Artemis spaceflight moon missions, providing its 2nd and 3rd LVSA units which further solidify our prominence in designing and building spaceflight hardware,” stated Jan Hess, President of Teledyne Brown Engineering. “We are proud to continue our decades long partnership with MSFC, where our teams have worked tirelessly to help propel our nation beyond the Earth’s gravity.”

Artemis II is planned to launch in 2023 on a crewed mission to perform a lunar flyby. Artemis III is currently scheduled to launch in 2024, as the second crewed Artemis mission. It will include a landing at the Moon’s south polar region where two astronauts, including the first woman to walk on the moon, will reside for a week.

Teledyne Brown Engineering is contracted to provide the engineering, technical support, and hardware to NASA for two additional LVSA units. The company delivered the LVSA Structural Test Article in 2016 and Flight Unit 1 in July 2020.

About Teledyne Brown Engineering

Teledyne Brown Engineering is an industry leader in full-spectrum engineering and advanced manufacturing solutions for harsh environments in space, defense, energy, and maritime industries. For over six decades, the company has successfully delivered innovative systems, integration, operations and technology development worldwide. For more information, visit Teledyne Brown Engineering’s website at www.tbe.com.

About Teledyne Technologies Incorporated

Teledyne Technologies is a leading provider of sophisticated instrumentation, digital imaging products and software, aerospace and defense electronics, and engineered systems. Teledyne’s operations are primarily located in the United States, Canada, the United Kingdom, and Western and Northern Europe. For more information, visit Teledyne’s website at www.teledyne.com.

Investor Contact:

Jason VanWees

(805) 373-4542

Media Contact:

Jessica Sanders

(256) 726-1385

KEYWORDS: United States North America California Alabama

INDUSTRY KEYWORDS: Software Other Defense Contracts Hardware Electronic Design Automation Technology Defense Other Manufacturing Engineering Aerospace Other Technology Manufacturing

MEDIA:

Logo
Logo

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against MultiPlan Corporation – MPLN

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against MultiPlan Corporation – MPLN

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of MultiPlan Corporation (NYSE: MPLN) resulting from allegations that MultiPlan may have issued materially misleading business information to the investing public.

On November 11, 2020, Muddy Waters Research published a report entitled “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab[.]” The Muddy Waters report described a series of issues involving MultiPlan including that “MPLN is in the process of losing its largest client, UnitedHealthcare (‘UHC’). UHC has formed a competitor to MPLN that offers significantly lower prices and fewer conflicts of interest.”

On this news, MultiPlan’s stock price fell $2.46 per share, or 28%, over the next two trading days to close at $6.27 per share on November 12, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of MultiPlan shareholders. If you purchased securities of MultiPlan please visit the firm’s website at http://www.rosenlegal.com/cases-register-1983.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Extendicare Announces 2020 Third Quarter Results

MARKHAM, Ontario, Nov. 12, 2020 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and nine months ended September 30, 2020. Results are presented in Canadian dollars unless otherwise noted.

“Combatting the recent surge in COVID-19 cases is the top priority for our organization,” said President and Chief Executive Officer, Dr. Michael Guerriere. “We have learned a lot from our experience with COVID-19 and have applied these learnings to enhance our processes to mitigate the risk posed by the pandemic. From routine testing for staff, to the creation of rapid response teams that can assist locations that are experiencing COVID-19 challenges, we remain steadfast in our efforts to protect our residents, clients and staff.”

“While we focus on safety in our day-to-day operations, we are also making significant investments in people and infrastructure to build a better future for seniors,” added Dr. Guerriere. “In the face of an increasing shortage of personal support workers, we have established a caregiver training program where Extendicare provides tuition and paid, on-the-job training for qualified applicants and a guaranteed job upon graduation. We aim to expand this program to train more than 600 new hires per year to help address what is a critical, industry-wide need. We are also pleased to announce the start of construction on a 256-bed long-term care home in Sudbury to replace one of our older homes. These important long-term investments in people and infrastructure will improve conditions for residents and employees, while also adding value for all stakeholders.”

COVID-19 Update

During the second quarter, Extendicare took decisive steps to prepare for the “second wave” of COVID-19 now underway across Canada. These actions included routine testing of staff in cooperation with local public health authorities, increased staffing in long-term care (LTC) homes, bolstering inventory of personal protective equipment (PPE) and the introduction of an experienced rapid response team to assist homes in outbreak, among other initiatives. While these actions have helped mitigate the impact of COVID-19 in our homes, the sharp rise in cases in surrounding communities has caused a resurgence of outbreaks.

As of today, of our 69 long-term care homes and retirement communities, 12 LTC homes are in outbreak, with the majority limited to three or fewer active cases of COVID-19 among residents and staff. We are also working closely with our Extendicare Assist clients to help them manage outbreaks in their homes.

We continue to believe that routine testing, effective use of PPE and frequent sanitizing are the best preventative measures currently available to stop the spread of the virus in Extendicare’s network of LTC homes and retirement communities until vaccines are widely available. Extendicare is working closely with government, health authorities, industry partners and advocacy groups on initiatives to help ensure our collective response to the crisis is optimized for the protection and care of our residents, clients and staff.

To combat the pandemic, we have spent an estimated $42.5 million in operating and administrative expenses, partially offset by $22.7 million from various provincial government pandemic programs, resulting in a reduction of our consolidated net operating income (NOI) and Adjusted EBITDA of approximately $17.0 million and $19.8 million, respectively. We have dispensed a further estimated $33.6 million in pandemic pay, fully funded by programs announced by the Ontario and Alberta governments, to temporarily increase hourly wages for certain eligible front-line employees. In addition, we have an additional $9.7 million in PPE inventory to ensure that we continue to have sufficient supply.  

Our operations continue to be affected by COVID-19, with lower occupancy levels in our LTC homes and retirement communities and costs in excess of funding levels. Home health care volumes continue to recover as referrals have returned to pre-pandemic levels.  However, volumes are taking longer to recover due to COVID-19 related shortfalls in our workforce capacity. 

Executive Appointment

Dr. Matthew Morgan joined Extendicare in the newly-created role of Chief Medical Officer on October 19, 2020. His focus is on developing and coordinating the implementation of clinical strategies that result in better outcomes for residents, clients and their families. Dr. Morgan is a practicing General Internal Medicine physician with a Masters in Clinical Epidemiology, and an Assistant Professor in the Faculty of Medicine at the University of Toronto.

Factors Impacting Comparability of Financial Results for 2020

For purposes of the Financial Highlights and Business Update sections, revenue, NOI and NOI margins exclude the year-over-year decline in revenue resulting from the expiration of ParaMed’s B.C. home health care contracts in Q1 2020,  the incremental funding related to Bill-148 received by ParaMed in Q2 2019, and the increase in NOI  from the $50.8 million received by ParaMed under the Canada Emergency Wage Subsidy (CEWS) program in Q3 2020 (recorded as an offset to operating expenses of the home health care segment), as discussed under the Home Health Care business update below.

In addition, the recognition of pandemic-related costs and the timing of the recognition and receipt of related government funding and subsidies has resulted in volatility in our quarterly results which is expected to continue throughout the remainder of the pandemic.

Financial Highlights

Q3 2020 (all comparisons with Q3 2019)

  • Revenue up 10.1% or $27.2 million to $296.8 million; driven by COVID-19 funding of $28.7 million, LTC funding enhancements and growth in retirement living and other operations, partially offset by a 9.9% decline in home health care average daily volumes (ADV).
  • Net operating income (NOI)(1) of $25.2 million, down 27.6% or $9.6 million; reflecting COVID-19 costs in excess of funding of $7.2 million, costs of resident care in excess of funding in LTC and lower ADV and increased workers compensation and benefits costs in home health care, partially offset by growth in the retirement living and other operations segments.
  • Adjusted EBITDA(1) up $39.9 million to $63.8 million; reflecting the underlying decline in NOI noted above and increase in administrative costs, offset by CEWS.
  • Earnings from continuing operations up $29.3 million to $34.6 million; primarily driven by CEWS, as noted above for ParaMed ($37.3 million net of tax), partially offset by estimated COVID-19 costs in excess of funding ($6.4 million net of tax) and the volume driven decline in NOI of the home health care segment.
  • AFFO(1) of $42.8 million ($0.48 per basic share), up $29.1 million; reflecting the increase in earnings from continuing operations (including impact of CEWS and estimated costs of COVID-19 in excess of funding, net of tax, of $30.9 million or $0.35 per basic share).
  • Earnings from discontinued operations included a release of the Company’s captive’s reserves of $2.0 million in the prior year.

Nine Months 2020 (all comparisons with Nine Months 2019)

Excluding the factors impacting comparability noted above, results for the nine months ended September 30, 2020 reflect growth in the retirement living and other operations segments and LTC funding enhancements, partially offset by COVID-19 costs in excess of funding, a 11.3% decline in home health care ADV, higher home health care operating costs and increased administrative costs.

  • Revenue up 5.7% or $46.0 million to $847.6 million.
  • NOI(1) of $75.5 million, down 23.7% or $23.4 million.
  • Adjusted EBITDA(1) up $23.3 million to $92.1 million; reflecting the underlying decline in NOI noted above and increase in administrative costs related to COVID-19, offset by CEWS.
  • Earnings from continuing operations up $16.7 million to $27.0 million; primarily driven by CEWS ($37.3 million net of tax) and largely offset by estimated COVID-19 costs in excess of funding ($14.5 million net of tax) and the volume driven decline in NOI of home health care operations.
  • AFFO(1) of $57.4 million ($0.64 per basic share), up $16.1 million; reflecting the increase in earnings from continuing operations (including impact of CEWS and estimated costs of COVID-19 in excess of funding, net of tax, of $22.8 million or $0.26 per basic share).
  • Earnings from discontinued operations up $1.5 million to $9.7 million; reflecting releases of the Company’s captive’s reserves of $9.5 million compared to $6.4 million in the prior year, and a $1.9 million reduction in foreign exchange and fair value adjustments.
  • Dividends declared of $32.2 million in 2020, representing approximately 56% of AFFO.

Business Updates

The following is a summary of the Company’s revenue, NOI and NOI margins by business segment for the three and nine months ended September 30, 2020 and 2019.

(unaudited) Three months ended September 30   Nine months ended September 30
(millions of dollars, unless otherwise noted) 2020   2019     2020   2019  
Revenue                  
Long-term care 184.7   161.0     523.4   477.1  
Retirement living 12.0   10.4     35.8   29.9  
Home health care 93.2   92.3     268.8   276.8  
Other 6.8   5.9     19.6   17.7  
Total revenue 296.8   269.6     847.6   801.6  
NOI and NOI margin
(1)
                 
Long-term care 13.0
7.0

%
20.6 12.8 %   42.5
8.1

%
56.9 11.9 %
Retirement living 3.2
26.9

%
2.9 28.3 %   10.4
29.2

%
8.4 28.2 %
Home health care 4.7
5.1

%
8.0 8.7 %   10.4
3.9

%
23.7 8.6 %
Other 4.3
62.7

%
3.2 53.9 %   12.1
61.9

%
9.8 55.4 %
Total NOI and NOI margin
(1)
25.2
8.5

%
34.8 12.9 %   75.5
8.9

%
98.9 12.3 %
Note:  Totals may not sum due to rounding.


Long-term Care

Long-term care operations continue to be impacted by increased costs associated with COVID-19. In Q3 2020, the increased operating expenses resulted in lower NOI compared to the same period last year.

NOI and NOI margin in Q3 2020 were $13.0 million and 7.0%, respectively, down from $20.6 million and 12.8% respectively in Q3 2019. NOI and NOI margin decreased in the quarter largely as a result of increased costs of resident care, including costs associated with COVID-19 and pandemic pay programs, estimated to be $27.7 million and $6.6 million in excess of government funding received.

Average occupancy dropped to 90.0% in Q3 2020, down 790 bps from Q3 2019 and 350 bps from Q2 2020, mainly driven by reduced admissions as a result of COVID-19. Despite lower occupancy levels, our revenue base is largely protected as full funding is preserved in Ontario for the remainder of the year, and each of the western provinces in which we operate have introduced additional funding to offset the impact of COVID-19. 

During the third quarter, the Ontario Ministry of Long-Term Care provided updates to its Long-Term Care Home Capital Development Funding program for the development of new and replacement LTC beds. The program includes a $1.75 billion investment to redevelop 12,000 beds and add an additional 8,000 beds over the next five years.

We have submitted applications to the Ontario Ministry of Long-Term Care in respect of 22 projects to build over 4,200 beds to replace all of our existing 3,287 C-class beds and to add new LTC beds, in keeping with the Ontario government’s focus on replacing aging infrastructure and increasing the number of LTC beds in the province. We continue to work closely with our industry partners and government to further enhance the new capital development funding program, in particular, to address certain geographic areas and streamline the related approval and licensing processes to expedite those projects that are currently feasible.

In October 2020, we received all of the necessary approvals to commence construction of a new 256-bed LTC home in Sudbury, Ontario that will replace our 234-bed Extendicare Falconbridge C-class bed home. Construction will commence in Q4 2020, with completion anticipated in Q4 2022, and the redevelopment represents an investment of $62.3 million in our LTC segment.


Home Health Care

In Q3 2020, revenue was largely unchanged at $93.2 million, up 1.0% from Q3 2019, as the impact of COVID-19 and pandemic pay funding of $7.6 million was largely offset by lower ADV, down 9.9% compared to same quarter last year.

NOI and NOI margin decreased to $4.7 million and 5.1%, respectively, in Q3 2020, down from $8.0 million and 8.7%, respectively, in Q3 2019. NOI declined largely as a result of lower business volumes and workers compensation and benefits costs. In addition, NOI was impacted by costs associated with COVID-19 and pandemic pay in excess of funding.

The peak impact of COVID-19 on ADV occurred in April 2020. Since that time, we have seen a gradual recovery in ADV with Q3 2020 showing an 11.6% increase from Q2 2020 and a further increase of 5.2%, to 23,934, in ADV for the four weeks ended November 8, 2020. While referrals have recently returned to pre-COVID levels our business volumes have been slower to recover due to COVID-19 related shortfalls in our workforce capacity. 

The volume declines and resultant revenue decreases experienced in our home health care operating subsidiary, ParaMed Inc., resulted in ParaMed applying for, and receiving, a payment under the CEWS program in Q3 2020. The CEWS program was established by the Federal Government to help Canadian employers that have experienced revenue declines to re-hire workers laid off as a result of COVID-19, to  prevent further job losses and to better position the employers to resume normal operations after the COVID-19 pandemic. ParaMed received a payment of $50.8 million under the CEWS program in Q3 2020 for claim periods from March 15, 2020 to July 4, 2020. Subsequent to September 30, 2020, ParaMed applied for and received an additional $31.4 million in CEWS for the claims periods from July 5, 2020 to September 26, 2020. ParaMed anticipates filing for additional CEWS funding contingent on changes to the CEWS program and the rate of volume recovery in subsequent periods. The CEWS is recorded as an offset to operating expenses, positively impacting the NOI of the home health care segment for the three and nine months ended September 30, 2020. 

Throughout this period, we have remained focused on maintaining our workforce capacity to ensure we are able to respond quickly to increases in demand for home health care services and resume operating at normalized levels as the pandemic recedes. In addition, we are making long-term investments to address the shortage of personal support workers that has challenged our industry for years, and has been more recently exacerbated by the pandemic. We have developed in-house programs and partnered with colleges to create a new supply of skilled caregivers. For example, under a program launched earlier this year, ParaMed is covering college tuition and providing paid on-the-job training, followed by full employment to new entrants to the home health care sector. To date, we have graduated approximately 200 new caregivers through the program, and we expect the capacity to increase to more than 600 students per year as we partner with additional colleges.

As the stream of graduates from our training programs increases and remaining staff return to the workforce, we anticipate continued improvement in ADV. While we cannot predict the ultimate impact nor the duration of the pandemic, we are focused on managing our operations through this challenge so we are well positioned to continue to provide high quality care and expand our operations when the pandemic recedes.


Retirement Living

Our retirement living operations continued to deliver solid financial results as contributions from non same-store operations and lease-up communities more than offset the negative impact of COVID-19 on occupancy and cost levels.

In Q3 2020, revenue increased to $12.0 million, up 15.1% from the same quarter last year, largely driven by the opening of The Barrieview in October 2019 and partially offset by the impact of COVID-19 on occupancy levels at our stabilized communities. NOI in the third quarter increased by 9.5% to $3.2 million, reflecting the increase in revenue; however, lower same-store occupancy levels and increased costs associated with COVID-19 led to lower NOI margin of 26.9%, down from 28.3% from the same quarter last year.

As a result of the recommencement of in-person tours in Ontario in Q3 2020, average occupancy of our stabilized portfolio improved to 91.9% in Q3 2020, up from 91.5% in Q2 2020. Despite this rebound from the prior quarter, levels remain below Q3 2019 of 94.0% as a result of the impacts of COVID-19.

Stabilized occupancy improved through the third quarter, increasing by 180bps from Q2 2020 to 93.1% as at September 30, 2020. Subsequent to quarter end, in-person tour restrictions were re-introduced in certain regions in Ontario and stabilized occupancy decreased to 91.7% as at October 31, 2020. We continue to actively market our properties and conduct virtual tours in place of in-person visits.


Other Operations

Financial performance in our other operations remained strong as revenue increased 15.2% to $6.8 million, largely driven by growth in our SGP Purchasing Partner Network (SGP). NOI also increased in the quarter, up 34.0% to $4.3 million, as our growing SGP client base and lower travel and business promotion costs offset increased staff costs. The number of third-party residents served by SGP increased to approximately 79,400 at the end of the third quarter, up 23.5% from September 30, 2019, and 5.6% from June 30, 2020.


Financial Position

Extendicare maintained its strong financial flexibility and liquidity in Q3 2020, with cash and cash equivalents on hand of $170.1 million and access to a further $71.3 million in undrawn demand credit facilities as at September 30, 2020. Following financing activities in the first half of 2020 to extend and renew existing mortgages on LTC homes and to finalize new mortgages on retirement communities, the Company does not have any scheduled debt maturities until Q1 2022.  

Select Financial Information

The following is a summary of the Company’s consolidated financial information for the three and nine months ended September 30, 2020 and 2019.

(unaudited) Three months ended

September 30
(2)


  Nine months ended

September 30
(2)
(thousands of dollars unless otherwise noted) 2020   2019     2020   2019  
Revenue 296,786   282,733     850,551   841,055  
Operating expenses 220,810   247,866     724,258   740,482  
NOI
(1)
75,976   34,867     126,293   100,573  
      NOI margin
(1)

25.6

%
12.3 %   14.8 % 12.0 %
Administrative costs 12,182   11,021     34,201   31,801  
Adjusted EBITDA
(1)
63,794   23,846     92,092   68,772  
      Adjusted EBITDA margin
(1)

21.5

%
8.4 %   10.8 % 8.2 %
Other expense       2,780   2,404  
Earnings from continuing operations 34,644   5,353     26,992   10,332  
per basic share ($) 0.39   0.06     0.30   0.12  
per diluted share ($) 0.36   0.06     0.30   0.12  
Earnings from discontinued operations, net of tax (178 ) 1,906     9,721   8,210  
Net earnings (loss) 34,466   7,259     36,713   18,542  
per basic share ($) 0.38   0.08     0.41   0.21  
per diluted share ($) 0.36   0.08     0.41   0.21  
AFFO
(1)
42,787   13,693     57,363   41,235  
per basic share ($) 0.48   0.15     0.64   0.46  
per diluted share ($) 0.44   0.15     0.61   0.45  
Current income tax expense (recovery) included in FFO 14,118   2,666     14,343   7,477  
      FFO effective tax rate
25.9

%
17.9
%

 

22.3

%
17.6
%
Maintenance capex 2,381   3,056     6,293   6,284  
Cash dividends declared per share 0.12   0.12     0.36   0.36  
Payout ratio
(1)
25 % 78 %   56 % 78 %
Weighted average number of shares
(thousands)
                 
Basic 89,864   89,253     89,778   89,040  
Diluted 100,223   99,614     100,145   99,412  
(1)   

Non-GAAP Measures:

Extendicare assesses and measures operating results and financial position based on performance measures referred to as “net operating income”, “NOI”, “NOI margin”, “Adjusted EBITDA”, “Adjusted EBITDA margin”, “AFFO”, “AFFO per share”, and “payout ratio”. In addition, the Company assesses its return on investment in development activities using the non-GAAP financial measure “NOI Yield”. These are not measures recognized under GAAP and do not have standardized meanings prescribed by GAAP. These non-GAAP measures are presented in this document because either: (i) management believes that they are a relevant measure of the ability of Extendicare to make cash distributions; or (ii) certain ongoing rights and obligations of Extendicare may be calculated using these measures. Such non-GAAP measures may differ from similar computations as reported by other issuers and, accordingly, may not be comparable to similarly titled measures as reported by such issuers. They are not intended to replace earnings (loss) from continuing operations, net earnings (loss), cash flow, or other measures of financial performance and liquidity reported in accordance with GAAP. Detailed descriptions of these terms can be found in Extendicare’s disclosure documents, including its Management’s Discussion and Analysis, filed with the securities regulatory authorities; these documents are available at www.sedar.com and on Extendicare’s website at www.extendicare.com.
(2)   
Comparative figures have been re-presented to reflect discontinued operations.

Extendicare’s financial reports, including its Management’s Discussion and Analysis are available on its website at www.extendicare.com under the “Investors/Financial Reports” section.

November Dividend Declared

The Board of Directors of Extendicare today declared a cash dividend of $0.04 per share for the month of November 2020, which is payable on December 15, 2020, to shareholders of record at the close of business on November 30, 2020. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada).

Conference Call and Webcast

On November 13, 2020, at 11:30 a.m. (ET), Extendicare will hold a conference call to discuss its 2020 third quarter results. The call will be webcast live and archived online at www.extendicare.com under the “Investors/Events & Presentations” section. Alternatively, the call-in number is 1-800-319-4610 or 416-915-3239. A replay of the call will be available approximately two hours after completion of the live call until midnight on November 27, 2020. To access the rebroadcast dial 1-800-319-6413 followed by the passcode 5368#.

About Extendicare

Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, Esprit Lifestyle, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. We are committed to delivering quality care throughout the health continuum to meet the needs of a growing seniors population. We operate or provide contract services to a network of 122 long-term care homes and retirement communities (69 owned/53 contract services), provide approximately 8.5 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 79,400 senior residents across Canada. Our qualified and highly trained workforce of approximately 23,000 individuals is passionate about providing high quality services to help people live better.


Forward-looking Statements

This press release contains forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation, statements regarding its business operations, business strategy, and financial condition
, including anticipated timelines, costs and financial returns in respect of development projects,
and in particular statements in respect of the impact of measures taken to mitigate the impact of COVID-19, the availability of various government programs and financial assistance announced in respect of COVID-19, the impact of COVID-19 on the Company’s operating costs, staffing, procurement, occupancy levels (primarily in its retirement communities) and volumes in its home health care business, the impact on the capital and credit markets and the Company’s ability to access the credit markets as a result of COVID-19, increased litigation and regulatory exposure and the outcome of any litigation and regulatory proceedings. Forward-looking statements can be identified because they generally contain the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “objective”, “plan”, “project”, “will” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and Extendicare assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Extendicare to differ materially from those expressed or implied in the statements. Risks and uncertainties related to the effects of COVID-19 on Extendicare include the length, spread and severity of the pandemic; the nature and extent of the measures taken by all levels of governments and public health officials, both short and long term, in response to COVID-19; domestic and global credit and capital markets; the Company’s ability to access capital on favourable terms or at all due to the potential for reduced revenue and increased operating expenses as a result of COVID-19; the availability of insurance on favourable terms; litigation and/or regulatory proceedings against or involving the Company, regardless of merit; the health and safety of the Company’s employees and its residents and clients; and domestic and global supply chains, particularly in respect of personal protective equipment. Given the evolving circumstances surrounding COVID-19, it is difficult to predict how significant the adverse impact will be on the global and domestic economy and the business operations and financial position of Extendicare. For further information on the risks, uncertainties and assumptions that could cause Extendicare’s actual results to differ from current expectations, refer to “Risk Factors” in Extendicare’s Annual Information Form and “Forward Looking-Statements” in Extendicare’s Q2 2020 Management’s Discussion and Analysis filed by Extendicare with the securities regulatory authorities, available at www.sedar.com and on Extendicare’s website at www.extendicare.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare’s forward-looking statements.

Extendicare contact:
David Bacon
Senior Vice President and Chief Financial Officer
Phone: (905) 470-4000; Fax: (905) 470-4003
Email: [email protected]
www.extendicare.com

 

Relay Medical & Fio Announces Over $500,000 CAD in Contracts for Fionet Mobile COVID-19 Testing & Tracking Platform; Provides Operational Update

  • Relay & Fio joint venture, Fionet Rapid Response Group, announce over $500,000 CAD in initial contracts
  • Fionet is a first-of-its-kind mobile testing & tracking platform designed to administer widespread rapid testing, for infectious diseases including COVID-19, and capture real-time data & insights
  • FRR has begun platform configuration with COVID-19 rapid diagnostic tests from Abbott, Roche and Proprietary Innovation Labs, positioning Fionet to support some of the most widely accessible COVID-19 tests in the world
  • FRR takes delivery of the first production run of mobile testing devices from its Minneapolis-based contract manufacturing partner KeyTronic (NASDAQ: KTCC)

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”), together Fionet Rapid Response Group (“FRR”) are pleased to provide an update on contracts exceeding $500,000 CAD.

In an alliance with South Korean rapid diagnostic test (RDT) maker, IVD Lab Co, FRR announces a contract with funding assistance provided by the National Research Council Canada (NRC) to bring to market a new type of RDT that can greatly ease the burden on hospitals and save lives. Validation of this innovative RDT has started at UHN in Toronto, North America’s largest teaching and research hospital.

Fio Corporation holds the IP on the combination of biomarkers that made this test possible. South Korea is a country noted for outstanding production quality of RDTs.

This innovative RDT, for use alongside rapid tests that diagnose infectious diseases, is a simple blood test designed to distinguish those infected patients who are at great risk to become critically ill (and hence will need hospitalization) from those who will safely recover at home. US hospital capacity is now capped, yet the number of COVID-infected people is growing. To prevent death toll skyrocketing, it will be indispensable to keep hospital beds for those that will really need them. This test is designed to predict critical illness, or sepsis, in infectious diseases, and will be paired to the Fionet Device.

In Kenya, FRR has completed the deployment of Fionet in 10 primary care healthcare facilities in Kenya. The Fionet Patient manager is used for reception, triage, clinical consultation, lab, and pharmacy, including a COVID-19 screening module. FRR team provided configuration services, training, and support to the local teams and currently, the Fionet platform is currently producing reports for the Meru department of health to submit to the Kenya ministry of health.

“This deployment in Kenya demonstrates the flexibility and data management strength of Fionet. To control a pandemic, testing in the community must be fused with real-time data capture and distribution, not only when they show up for testing, but also as they follow through with treatment,” said Dr. Michael Greenberg, CEO of Fionet Rapid Response Group and CEO of Fio Corporation.

In addition, FRR is in negotiation with several other leading healthcare organizations around the world to pilot and/or deploy Fionet to support rapid testing programs for COVID-19 and other infectious diseases.

Fionet begins configuring platform for multiple leading COVID-19 rapid diagnostic tests

FRR is pleased to announce it has successfully received multiple COVID-19 lateral flow rapid diagnostic tests that will be configured to operate with the Fionet platform:

  • Abbott Panbio COVID-19 Ag Rapid Test. The test is CE marked and approved by Health Canada for point of care diagnosis. Abbott Panbio is being used across Europe and Africa and recently, the Government of Canada announced the purchase of 20 million tests to be used by public health authorities to combat the pandemic1.
  • Roche SARS-CoV-2 Rapid Antigen Test. The test is CE marked for markets accepting the designation including the European Union. Roche previously indicated that it will be able to produce up to 100 million tests per month to distribute worldwide2.
  • Proprietary Innovation Labs Antibody and Antigen Tests. Relay Medical recently announced the signing of an LOI for the exclusive sales and distribution rights of these tests. Both tests are CE marked with potential production capacity of 25 million per month.

With these tests on hand, development activities will commence to configure the Fionet software and analysis engine to be compatible with identifying, error checking and interpretation of results. Onboarding of the tests will support trial or pilot deployments for upcoming clients.

Production of Mobile Testing Device

FRR is pleased to announce the delivery of the first production run of the new COVID-19 mobile testing devices from its contract manufacturer KeyTronic (NASDAQ: KTCC). This initial run of devices will be used for verification activities, onboarding of rapid diagnostic tests and supporting initial pilots. FRR expects to receive additional devices from the pilot run within the next 2 weeks as part of its first order to activate the assembly line.

_______________________________
1https://www.canada.ca/en/public-services-procurement/news/2020/10/government-of-canada-signs-new-agreement-for-covid-19-rapid-tests.html
2https://www.roche.com/media/releases/med-cor-2020-09-01b.htm



**The Companies are not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

About Fio Corporation

Fio Corporation, privately held and headquartered in Toronto, developed and markets the world’s first integrated guidance & tracking IT platform for decentralized healthcare settings, a new category of solution that raises healthcare quality and lowers healthcare costs. The platform enables average healthcare workers in clinics to deliver a new level of quality-controlled diagnostic testing and case management. Simultaneously, as an automated by-product of its clinical use, the platform captures and provides unprecedented frontline data to remote supervisors and stakeholders, enabling real-time remote tracking, insight distribution, and intervention. Fio operates globally in partnership with local distribution, service, and support organizations and also partners with other companies that license its technologies.

Website: www.fio.com

About Relay Medical Corp.

Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.

Website: www.relaymedical.com

Contact:

W. Clark Kent
President
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
[email protected]

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: [email protected]

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law.   Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur.   Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE.  There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control.  There are no assurances that the commercialization plans for the Company’s technologies described in this news release will come into effect on the terms or time frame described herein.   The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law.   The reader is cautioned not to place undue reliance on forward-looking statements.   Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c73e26ec-59f6-4967-825e-53d60a7386d5